Bile Acids: From Genomics to Disease and Therapy

List of Principal Contributors. Preface. Pathways and regulation of bile acid synthesis; J.B. Cheng, D.W. Russell. <strong>Section I: Regulation</strong> <strong>of Gene Expression by Bile Acids. 1.</strong> The homeostatic control of bile acid biosynthesis and transport by nuclear receptors; C.J. Sinal, F.J. Gonzales. <strong>2.</strong> Coordinated regulation of hepatobiliary transporter genes by nuclear receptors; S. Karpen. <strong>3.</strong> Transactivation of the human OATP8 gene by the Farnesoid X Receptor/Bile Acid Receptor (FXR/BAR); G.A. Kullak-Ublick, D. Jung. <strong>Section II: Synthesis and Metabolism of Bile</strong> <strong>Acids. 4.</strong> Vitamin D receptor as a bile acid sensor; T.T. Lu, et al. <strong>5.</strong> Molecular mechanisms of nuclear receptor regulation of bile acid synthesis; J.Y.L. Chiang, et al. <strong>6.</strong> Manipulating the bile acid pool regulates CYP7A1 by changing FXR activation; Guorong Xu, et al. <strong>Section III: Transport of Bile Acids and Bile Secretion. 9.</strong> Mutations in the sodium-independent bile salt uptake transporter of human liver SLC21A6; J. König, et al. <strong>10.</strong> Regulation of the rat organic anion transporting polypeptide 4 (Oatp4) by bile acids; D.Rost, et al. <strong>11.</strong> Regulation of expression and function of the canalicular bile acid export pump; P. Meier-Abt. <strong>12.</strong> The in-vivo and in-vitro function of human BSEP; R. Thompson. <strong>13.</strong> Sinusoidal efflux of bile acids; H.Akita, et al. <strong>14.</strong> Organ-specific regulation of nuclear hormone receptors and bile salt transport proteins in obstructive cholestasis; A. Bohan, et al. <strong>Section IV: Bile Acids in Disease. 22.</strong> Acquired alterations of hepatobiliary transport systems in human cholestatic liver diseases: potential targets of pharmacotherapy; M. Trauner, et al. <strong>23.</strong> Bilary lipid composition in BRIC patients; R.H.J. Houwen, et al. <strong>24.</strong> Mutations in MDR3 in adult onset cholangiopathy; S. Strautnieks, et al. <strong>25.</strong> MDR3 gene mutations and cholesterol cholelithiasis; O. Rosmorduc, et al. <strong>26.</strong> Expression and localization of hepatobiliary transporters in primary biliary cirrhosis; H. Kojima, et al. <strong>27.</strong> Neonatal liver disease in two siblings caused by a failure to racemize (25R)trihydroxy-cholestanoic acid due to a gene mutation in 2-methylacyl-CoA racemase: Effectiveness of cholic acid therapy in preventing liver and neurological disease; K.D.R. Setchell, et al. <strong>Section V: Bile Acids in Therapy. 28.</strong> UDCA and TUDCA ameliorate hepatocyte damage caused by EtOH and acetaldehyde by different mechanisms; U. Leuschner, et al. <strong>29.</strong> Ursodeoxycholic acid therapy affects the cytokine network and plays an immunomodulatory role in patients with primary sclerosing cholangitis and primary biliary cirrhosis; M.G. Neumann, et al. <strong>30.</strong> Dose response of UDCA in the treatment of cholestatic disorders; G. Mazzella, et al. <strong>31.</strong> High dose ursodeoxycholic acid in the management of primary sclerosing cholangitis; R.W. Chapman. <strong>32.</strong> Intrahepatic cholestasis of pregnancy: a placebo controlled randomised trial of ursodeoxycholic acid vs. dexamethasone on maternal and fetal outcome and metabolism; A Glantz, et al. <strong>33.</strong> Ursodeoxycholic acid in the chemoprevention of colon cancer; K. Kowdley. Index. Ten Additional Articles.